Basic information Safety Supplier Related

LY3023414

Basic information Safety Supplier Related

LY3023414 Basic information

Product Name:
LY3023414
Synonyms:
  • LY3023414
  • LY-3023414
  • 8-[5-(1-hydroxy-1-methylethyl)pyridin-3-yl]-1-[(2S)-2-methoxypropyl]-3-methyl-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one
  • LY3023414(Samotolisib)
  • LY3023414;LY-3023414;LY 3023414
  • CS-2814
  • GTPL8918
  • 2H-Imidazo[4,5-c]quinolin-2-one, 1,3-dihydro-8-[5-(1-hydroxy-1-methylethyl)-3-pyridinyl]-1-[(2S)-2-methoxypropyl]-3-methyl-
CAS:
1386874-06-1
MF:
C23H26N4O3
MW:
406.48
Mol File:
1386874-06-1.mol
More
Less

LY3023414 Chemical Properties

Boiling point:
591.7±50.0 °C(Predicted)
Density 
1.239±0.06 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
≥40.6 mg/mL in DMSO; insoluble in H2O; ≥28.9 mg/mL in EtOH
form 
solid
pka
13.65±0.29(Predicted)
color 
Light yellow to yellow
More
Less

LY3023414 Usage And Synthesis

Biological Activity

ly3023414 is an atp competitive inhibitor of the class i pi3k isoforms, mtor and dna-pk.the phosphoinositide-3 kinase (pi3k)/akt/mammalian target of rapamycin (mtor) pathway is one of the most frequently altered pathways in cancer cell growth and survival.

in vitro

in biochemical testing against approximately 266 kinases, ly3023414 was found to potently and selectively inhibit class i pi3k isoforms, mtorc1/2, as well as dna-pk at low concentrations. in addition, inhibition of pi3k/akt/mtor signaling by ly3023414 led to g1 cell-cycle arrest and resulted in broad antiproliferative activity in cancer cell panel [1].

in vivo

ly3023414 showed high bioavailability and dose-dependent dephosphorylation of pi3k/akt/mtor pathway downstream substrates for 4 to 6 hours, indicating ly3023414's half-life of 2 hours. moreover, equivalent total daily doses of ly3023414 given either once or twice daily could inhibit tumor growth to the similar extents in multiple xenograft models, demonstrating intermittent target inhibition was sufficient for antitumor activity [1].

target

TargetValue
class I PI3K isoforms
()
mTOR kinase
()
DNA-PK
()

IC 50

64.9, 42.1, 10.6, and 19.1 nm for akt1(pt308), akt1 (ps473), p70s6(pt389), and s6rp(ps240/242), respectively.

References

[1] smith mc,mader mm,cook ja,et al. characterization of ly3023414, a novel pi3k/mtor dual inhibitor eliciting transient target modulation to impede tumor growth. mol cancer ther.2016 oct;15(10):2344-2356.

LY3023414Supplier

Shanghai Boyle Chemical Co., Ltd.
Tel
Email
sales@boylechem.com
Haoyuan Chemexpress Co., Ltd.
Tel
021-58950125
Email
info@chemexpress.com
Shanghai Aladdin Bio-Chem Technology Co.,LTD
Tel
400-400-6206333 18521732826
Email
market@aladdin-e.com
ShangHai Caerulum Pharma Discovery Co., Ltd.
Tel
18149758185 18149758185
Email
sales-cpd@caerulumpharma.com
AdooQ Bioscience CHINA
Tel
025-58849295 18951903616;
Email
info@adooq.cn